Small Animal Internal Medicine

Research Abstract

ID02 - Clinical Evaluation of a Commercial Hyperimmune Plasma Product in Dogs with Parvoviral Enteritis

Thursday, June 14
4:15 PM - 4:30 PM
Location: WSCC 307/308

This randomized, placebo-controlled clinical trial prospectively evaluated the safety and clinical efficacy of a single infusion of hyperimmune plasma (HIP) when administered to dogs with canine parvovirus (CPV). Client-owned CPV dogs were randomized to receive either placebo [n =16, 0.9% NaCl (10 mL/kg IV)] or the study drug [n =16, HIP (10 mL/kg IV)] within the first six hours of hospital admission. Supportive care was standardized for both groups throughout the duration of hospitalization.

Dogs within the HIP group demonstrated a lower shock index at the 12-hour mark (p =0.046), and this difference was still observable at the 24-hour mark (p =0.04). Blood lactateconcentration was lower at the 24-hour mark in the HIP dogs when compared to the placebo dogs (p =0.049), although this was not statistically different at the 48-hour mark (p= 0.10). There was no difference in duration of hospitalization between groups (p= 0.35). Overall survival was 16/16 (100%) for the HIP group, compared to 14/15 (93.3%) for the placebo group (p =0.48). HIP was well tolerated with no adverse events noted during drug administration.

Results of this study indicate that hyperimmune plasma improves cardiovascular parameters during the first 24 hours of hospitalization. This study did not identify a difference in clinical severity improvement, duration of hospitalization, or mortality when comparing HIP and placebo dogs. Future studies evaluating HIP dose, and timing of HIP administration relative to disease onset, are needed to better determine the clinical benefit of this product.

Rachel Acciacca, DVM

Emergency and Critical Care Resident
Colorado State University

MAJ Rachel A. Acciacca is a native of Massachusetts and attended the University of Delaware where she received her Bachelors of Science in Animal Science. She earned her Doctorate of Veterinary Medicine from North Carolina State University in 2011.

MAJ Acciacca received a commission into the United States Army through the Reserve Officers’ Training Corps at the University of Delaware in 2007. Her active duty assignments include; Veterinary Clinical Intern, Department of Defense Military Working Dog Services Hospital, Lackland Air Force Base, TX; Branch Chief of Veterinary Services, Camp Lejeune Branch, Camp Lejeune, NC, Special Operations Forces (SOF) Veterinarian, US Marine Corps Forces Special Operations Command (MARSOC), Camp Lejeune, NC. She has deployed in support of Operation Inherent Resolve-Iraq (OIR-I) in support of the Combined Joint Special Operations Task Force-Iraq (CJSOTF-I) in 2016. MAJ Acciacca is currently a second year Small Animal Emergency and Critical Resident at Colorado State University.


Send Email for Rachel Acciacca


ID02 - Clinical Evaluation of a Commercial Hyperimmune Plasma Product in Dogs with Parvoviral Enteritis


Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Clinical Evaluation of a Commercial Hyperimmune Plasma Product in Dogs with Parvoviral Enteritis